Puma Biotechnology (NASDAQ:PBYI) Stock Passes Above 200 Day Moving Average - What's Next?

Key Points

• PBYI crossed above its 200-day moving average (200‑day MA $5.86) and traded as high as $7.02, closing near $6.97 on volume of 307,008 shares, suggesting positive technical momentum.
• The company reported an earnings beat (Q EPS $0.26 vs. $0.24 est., revenue $75.5M vs. $68.6M), trades at a P/E of 11.43 with a $354.6M market cap, and shows strong profitability metrics (ROE 27.8%, net margin 13.6%).
• Analyst sentiment is mixed—MarketBeat lists an average rating of Hold despite some upgrades to strong‑buy—and institutional investors own about 61.3% of the stock, indicating notable insider/hedge fund interest.

Puma Biotechnology, Inc. (NASDAQ:PBYI - Get Free Report) crossed above its 200-day moving average during trading on Tuesday . The stock has a 200-day moving average of $5.86 and traded as high as $7.02. Puma Biotechnology shares last traded at $6.97, with a volume of 307,008 shares.

Analyst Ratings Changes

PBYI has been the subject of several recent research reports. Weiss Ratings restated a "hold (c+)" rating on shares of Puma Biotechnology in a research note on Thursday, January 22nd. Wall Street Zen upgraded Puma Biotechnology from a "buy" rating to a "strong-buy" rating in a research note on Saturday, March 21st. One research analyst has rated the stock with a Hold rating, According to data from MarketBeat, Puma Biotechnology presently has an average rating of "Hold".

Puma Biotechnology Trading Up 1.2%

The business has a 50-day moving average price of $6.54 and a two-hundred day moving average price of $5.86. The stock has a market capitalization of $354.61 million, a P/E ratio of 11.43 and a beta of 1.19.

Puma Biotechnology (NASDAQ:PBYI - Get Free Report) last released its earnings results on Thursday, February 26th. The biopharmaceutical company reported $0.26 earnings per share for the quarter, beating analysts' consensus estimates of $0.24 by $0.02. Puma Biotechnology had a return on equity of 27.80% and a net margin of 13.62%.The firm had revenue of $75.50 million during the quarter, compared to the consensus estimate of $68.60 million. On average, sell-side analysts forecast that Puma Biotechnology, Inc. will post 0.31 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Puma Biotechnology

Institutional investors have recently modified their holdings of the business. Cerity Partners LLC acquired a new position in shares of Puma Biotechnology during the 2nd quarter worth $36,000. BNP Paribas Financial Markets raised its holdings in shares of Puma Biotechnology by 39.7% during the 3rd quarter. BNP Paribas Financial Markets now owns 8,056 shares of the biopharmaceutical company's stock worth $43,000 after buying an additional 2,290 shares in the last quarter. China Universal Asset Management Co. Ltd. acquired a new position in shares of Puma Biotechnology during the 4th quarter worth $49,000. State of Alaska Department of Revenue acquired a new position in shares of Puma Biotechnology during the 4th quarter worth $50,000. Finally, Caprock Group LLC acquired a new position in shares of Puma Biotechnology during the 3rd quarter worth $59,000. Institutional investors and hedge funds own 61.29% of the company's stock.

Puma Biotechnology Company Profile

Puma Biotechnology, Inc is a late‐stage biopharmaceutical company dedicated to the development and commercialization of targeted therapies for oncology patients. Founded in 2010 and headquartered in Los Angeles, California, the company focuses on advancing molecularly defined cancer treatments that address significant unmet medical needs.

The company's lead product is neratinib, marketed under the brand name Nerlynx in the United States. Neratinib is an irreversible small‐molecule tyrosine kinase inhibitor designed to target the HER2 receptor, and it received FDA approval in 2017 for extended adjuvant treatment of early‐stage HER2-positive breast cancer.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.